ASCO 2021 Highlights From IMpower 010 on Resected Stage IB-IIIA NSCLC: Atezolizumab vs. BSC After Adjuvant Chemotherapy

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

City of Hope

www.cityofhope.org

Breast
Lung
Gastrointestinal
Genitourinary
Leukemia
Lymphoma
Myeloma
Hematologic Malignancies
Head and Neck
General Oncology
Palliative Care
Events

Playback speed

10 seconds

ASCO 2021 Highlights From IMpower 010 on Resected Stage IB-IIIA NSCLC: Atezolizumab vs. BSC After Adjuvant Chemotherapy

By City of Hope FEATURING Jack West

584 views

July 1, 2021

This video was recorded prior to the FDA granting approval to Atezolizumab on 10/15/2021 as ...
read more ↘ adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC
↖ read less

Comments 0

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey

The First Treatment Choice Matters

Feat. A. Ip

Lung

WCLC 2024 Insights: Management of Radiation Toxicities in The Era of…

Insights from 2024 WCLC

P. Lee

92 views

Immunotherapy for SCLC - Best of Lung 2023

Total Health

J. Malhotra

119 views

Updates on Universal Comprehensive Genomic Profiling & Treatment Pla…

Total Health

R. Salgia

129 views

Novel Approaches in the Treatment of NSCLC

Total Health

E. Massarelli

359 views

ASCO® 2023 Insights: "LUNAR Trial Key Learnings & Clinical Implicati…

Insights from 2023 ASCO® Annual Meeting

J. West

50 views

ASCO® 2023 Insights: "KEYNOTE-671 Trial Key Learnings & Clinical Imp…

Insights from 2023 ASCO® Annual Meeting

J. West

963 views

Prevalence of EGFR Mutation Testing in Early Stage Lung Cancer: Impl…

City of Hope

E. Massarelli

181 views